CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase.
about
VNI cures acute and chronic experimental Chagas diseaseCYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffoldsCrystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infectionsSmall-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray CrystallographyX-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14 -Demethylase (CYP51)Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen HitStructural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and FluconazoleStructural Insights into Inhibition of Sterol 14 -Demethylase in the Human Pathogen Trypanosoma cruziSubstrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) from Leishmania infantumStructural complex of sterol 14 -demethylase (CYP51) with 14 -methylenecyclopropyl- 7-24, 25-dihydrolanosterolAntitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite GrowthComplexes of Trypanosoma cruzi Sterol 14 -Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease: STRUCTURAL BASIS FOR PATHOGEN SELECTIVITYStructural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its InhibitionDiscovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapyGenetic profiling of the isoprenoid and sterol biosynthesis pathway genes of Trypanosoma cruziSterol biosynthesis is required for heat resistance but not extracellular survival in leishmaniaA Multilayer Network Approach for Guiding Drug Repositioning in Neglected DiseasesSterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasisBiosynthesis of cholesterol and other sterolsTwo approaches to discovering and developing new drugs for Chagas disease.The Mycobacterium tuberculosis cytochrome P450 system.Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agentsCurrent and developing therapeutic agents in the treatment of Chagas diseaseStructural basis for conservation in the CYP51 family.Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasitica through inhibition of sterol 14α-demethylase (CYP51)Conformational dynamics in the F/G segment of CYP51 from Mycobacterium tuberculosis monitored by FRET.Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibitionDrug strategies targeting CYP51 in neglected tropical diseasesAzole Antifungal Agents To Treat the Human Pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through Inhibition of Sterol 14α-Demethylase (CYP51)Synergistic Interactions of Eugenol-tosylate and Its Congeners with Fluconazole against Candida albicansThe Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosaStructure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs.VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design.Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms
P2860
Q24604994-E9199BC5-2E08-4A85-AB22-DAF0D2DBDCB0Q24605691-9B950642-3245-42A7-883A-AA9AC9974C17Q24648110-21DCE1E6-B5CA-42AD-B232-176155599281Q27648016-188E5124-59F6-4B41-97F0-7F6E1AFA8FBCQ27650159-C00F5FBE-CB99-4CFB-9386-C20AC2290B56Q27653636-801690B3-4111-41EE-8B3C-E4AE226F62E5Q27660510-FABD920B-0272-4C0F-9E50-7FD704C11CADQ27662136-44DD41D5-7164-414B-AA31-D647A43DCC23Q27668116-8AFF3B14-6D9D-47F7-9589-E3A253D5F885Q27675909-8A4B1DDE-5CEE-4D81-8EAE-0A4ED09C2C33Q27676649-914EE8E8-D6DD-498A-AA8E-F3EBCD0431E2Q27679983-6FCFD988-D456-4049-B738-FA146BAFDA37Q27684715-110E1285-7D11-4AD7-B351-268A9D02465FQ28534270-497758BE-9CD8-43BD-98BE-872FF783FDEAQ28538787-6292C489-2FA3-4D23-9351-A9D2CE7DF730Q28544093-EC508794-A4B2-4656-9B29-B1323E182F99Q28552140-D512B630-4198-48E0-8C31-B5E860782476Q28727454-A1488DEC-BFD8-4215-9525-A49101065BB5Q28744002-5EC4069F-166B-4E92-BB9B-D04224859857Q33503274-61EEFF92-4D04-48C8-896C-E4119A7A1D41Q33615471-75CE9659-9C32-4BF8-BF81-3018D45D5C88Q33951320-E8DB10F0-636D-4007-83CF-B486D7323FB9Q34170132-492A5FC1-ADB9-42F4-9F54-2B666217A74FQ34233642-65F73769-E580-413E-A6F7-E0177A3DCC01Q34261359-BE0E9F26-EAF0-495A-85C6-7CB85C68BE7DQ34592594-7FE19B9E-B0F3-4FED-9A0D-349F138415C2Q34614864-96016B75-6ABE-452A-9468-3270020B8984Q34622554-26AA2058-21C3-468C-B2A9-9C16ECCF403FQ35642775-051288E1-27DD-4AFD-807E-DFCDBE2BDE96Q35875686-CAB26CF7-F82A-4639-91FD-79BA95EE32FEQ36012849-5DAB0C33-B09C-4B87-804D-A1063FD06C06Q36049722-F7A669A1-088C-4EF1-AA72-3AF3B7EBF6D2Q36093075-53D0D938-3E4C-41EA-998B-A73758BC0159Q36148993-8F3A2090-B8BD-4153-ACD3-8B98891317A3Q36366481-E68ADDB9-DE58-4308-8448-3ED475992D15Q36368984-8875DAB1-5AC0-4B30-BF4C-12A9313042D1Q36399175-66FBCEB1-B282-402C-B3A3-FF12F55200FCQ36571788-93630375-52C0-464D-9B4C-63EB406D0725Q36572552-25DCD83C-48F5-4D2B-A85F-948D9DEB6D16Q36572557-90D21DDA-EE2A-4A05-AF0B-5456756C1C34
P2860
CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@en
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@nl
type
label
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@en
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@nl
prefLabel
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@en
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@nl
P2093
P2860
P356
P1476
CYP51 from Trypanosoma cruzi: ...... of sterol 14alpha-demethylase.
@en
P2093
Galina I Lepesheva
George C Hill
Jialin Liu
Michael R Waterman
Miharu Arase
Natalia G Zaitseva
W David Nes
Wenxu Zhou
P2860
P304
P356
10.1074/JBC.M510317200
P407
P577
2005-11-30T00:00:00Z